Last reviewed · How we verify

NCT03220256

Protocol Establishment for the Prevention of Lamotrigine-induced Skin Rash in Epilepsy Patients

Status unknown Phase 2 Last updated 18 July 2017
What this trial tests

Phase 2 trial testing Lamotrigine in Lamotrigine Allergy in 30 participants. Status unknown.

Timeline
2 August 2016
Primary endpoint
1 August 2018
1 August 2018

Quick facts

Lead sponsorSeoul National University Hospital
PhasePhase 2
StatusStatus unknown
Study typeINTERVENTIONAL
Allocationna
Designsingle group
Maskingnone
Primary purposeprevention
Enrollment30
Start date2 August 2016
Primary completion1 August 2018
Estimated completion1 August 2018
Sites1 location across South Korea

Drugs / interventions tested

Conditions studied

Sponsor

Seoul National University Hospital

Who can join

Adults 18 to 85, any sex, with Lamotrigine Allergy. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The investigators intend to find a way to lower drug rash occurrence by applying drug tolerance induction protocol at the beginning of lamotrigine administration. Genotyping of participants with rash and those without rash after taking lamotrigine and genetic testing to find common gene mutations in these participants.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Lamotrigine

Trials testing the same drug.

Other Seoul National University Hospital trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03220256.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing